MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.8100
-0.0410
-4.82%
Closed 16:00 01/22 EST
OPEN
0.8500
PREV CLOSE
0.8510
HIGH
0.8540
LOW
0.8000
VOLUME
590.86K
TURNOVER
--
52 WEEK HIGH
1.730
52 WEEK LOW
0.5339
MARKET CAP
121.33M
P/E (TTM)
-2.1939
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LCTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LCTX News

  • BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why
  • Zacks.6d ago
  • Lineage Cell Therapeutics conducts sale of shares in OncoCyte
  • Seeking Alpha - Article.01/03 11:33
  • Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
  • Business Wire.01/03 01:00
  • Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration
  • Business Wire.12/30/2019 13:00

More

Industry

Biotechnology & Medical Research
+0.13%
Pharmaceuticals & Medical Research
-0.23%

Hot Stocks

Name
Price
%Change

About LCTX

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
More

Webull offers Lineage Cell Therapeutics Inc (LCTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.